Vera TherapeuticsVERA
VERA
About: Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Employees: 82
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
26% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 53
22% more call options, than puts
Call options by funds: $10.6M | Put options by funds: $8.7M
20% more capital invested
Capital invested by funds: $1.97B [Q2] → $2.36B (+$389M) [Q3]
1% more funds holding
Funds holding: 171 [Q2] → 173 (+2) [Q3]
8% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 25
2.21% less ownership
Funds ownership: 99.74% [Q2] → 97.53% (-2.21%) [Q3]
22% less funds holding in top 10
Funds holding in top 10: 9 [Q2] → 7 (-2) [Q3]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$38
11%
downside
Avg. target
$69
62%
upside
High target
$107
151%
upside
6 analyst ratings
5 positive
83%
1 neutral
17%
0 negative
0%
Wells Fargo Mohit Bansal 28% 1-year accuracy 7 / 25 met price target | 64%upside $70 | Overweight Initiated | 21 Nov 2024 |
Wedbush Laura Chico 32% 1-year accuracy 20 / 62 met price target | 11%downside $38 | Neutral Maintained | 8 Nov 2024 |
JP Morgan Anupam Rama 27% 1-year accuracy 16 / 59 met price target | 76%upside $75 | Overweight Maintained | 5 Nov 2024 |
Guggenheim Vamil Divan 40% 1-year accuracy 8 / 20 met price target | 50%upside $64 | Buy Maintained | 28 Oct 2024 |
Scotiabank Greg Harrison 33% 1-year accuracy 9 / 27 met price target | 41%upside $60 | Sector Outperform Initiated | 16 Oct 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on December 3, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 171,750 shares of Class A common stock and restricted stock units (RSUs) for 86,625 shares of Class A common stock to seventeen new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
4 weeks ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 18, 2024, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of a non-qualified stock option to purchase 108,000 shares of Class A common stock and restricted stock units (RSUs) for 53,000 shares of Class A common stock to Jason S. Carter, Vera's new Chief Legal Officer, under Vera's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Brisbane, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 4, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 54,050 shares of Class A common stock and restricted stock units (RSUs) for 27,025 shares of Class A common stock to seven new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet
The consensus price target hints at a 27.3% upside potential for Vera Therapeutics (VERA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
GlobeNewsWire
1 month ago
Vera Therapeutics to Participate at Upcoming Investor Conferences
BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences.
Neutral
GlobeNewsWire
1 month ago
Vera Therapeutics to Participate at Upcoming Investor Conferences
BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences.
Neutral
GlobeNewsWire
1 month ago
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
BRISBANE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an underwritten public offering of 7,142,858 shares of its Class A common stock at a price to the public of $42.00 per share.
Neutral
GlobeNewsWire
1 month ago
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
BRISBANE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $300.0 million of shares of its Class A common stock. All of the shares are being offered by Vera.
Positive
Benzinga
1 month ago
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years
On Saturday, Vera Therapeutics Inc. VERA released data from its ORIGIN Phase 2b trial of atacicept in immunoglobulin A nephropathy (IgAN), which showed stabilized kidney function through 96 weeks of long-term follow-up.
Positive
Investors Business Daily
1 month ago
Vera Therapeutics Eyes Breakout On Promising Results For Kidney Drug
Vera stock catapulted and briefly broke out on Monday after unveiling promising results for its kidney disease treatment.
Charts implemented using Lightweight Charts™